Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Investor Day (February 2013)
21 slides from Getinge Ab Class B's investor day presentation, Feb 8, 2013
Slide 1: Getinge Group Capital Market Day
GETINGE GROUP Capital Market Day Stockholm, 8 February 2013 Johan Malmquist, CEO Getinge Group
Slide 2: Overview & Future Direction
1 OVERVIEW & FUTURE DIRECTION 2 FINANCIAL TARGETS & HOW WE REACH THEM 3 OUTLOOK 2013 CAPITAL MARKET DAY 2013
Slide 3: Getinge Group
GETINGE GROUP Medical Systems Extended Care Infection Control CAPITAL MARKET DAY 2013
Slide 4: A successful journey 1993–2012
A successful journey 1993–2012 SEK billion Sales Profit before tax 30000 4000 3500 25000 3000 20000 2500 15000 2000 1500 10000 1000 5000 500 0 0 1993 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAPITAL MARKET DAY 2013
Slide 5: Getinge Group 2012
Getinge Group 2012 REVENUES ASSOCIATES SALES COMPANIES MANUFACTURING SITES SEK 27 Billion* 14 900 113 25 *annualized CAPITAL MARKET DAY 2013
Slide 6: Getinge Today
Getinge Today Competitive Business Global Footprint Market Leading Positions Well Positioned for the Future CAPITAL MARKET DAY 2013
Slide 7: Getinge has built a competitive business supported by a robust strategy
Getinge has built a competitive business supported by a robust strategy GLOBAL LEADERSHIP SOLUTION PROVIDER CUSTOMER RELATIONSHIPS CAPITAL MARKET DAY 2013
Slide 8: Future Ambition
Future Ambition GETINGE TODAY GETINGE TOMORROW SEK SEK Revenues Revenues 25 Billion 50 Billion Ebita margin ~20 % Ebita margin >22 % Market growth ~5 % Market growth 6-7 % Revenue OUS and OWE Revenue OUS and OWE 31% 35-40 as % of total revenue as % of total revenue CAPITAL MARKET DAY 2013
Slide 9: Financial Targets & How We Reach Them
1 OVERVIEW & FUTURE DIRECTION 2 FINANCIAL TARGETS & HOW WE REACH THEM 3 OUTLOOK 2013 CAPITAL MARKET DAY 2013
Slide 10: Getinge Group Financial Targets
Getinge Group Financial Targets Pre-tax earnings: Average growth of 15% per year Organic revenue growth 2% above market growth (normalized market growth ~5%) EBITA-margin ~22% Cash conversion: 60-70% of EBITDA CAPITAL MARKET DAY 2013
Slide 11: Financial Targets EBITA margin
Financial Targets EBITA margin % excl restructuring charges BUSINESS AREA 2012 TARGET 2015 MEDICAL SYSTEMS 22,5 % 24 % EXTENDED CARE 21,3 % 22 % INFECTION CONTROL 12,2 % > 16 % GROUP 20,0 % ~22 % CAPITAL MARKET DAY 2013
Slide 12: Planned Restructuring Charges
Planned Restructuring Charges (incl TSS & Atrium) BUSINESS AREA 2013 2014 2015 2016 MEDICAL SYSTEMS 40 – – – EXTENDED CARE 240 50 20 – INFECTION CONTROL 190 30 60 160 TOTAL 470 80 80 160 CAPITAL MARKET DAY 2013
Slide 13: Getinge Strategic Platform
Getinge Strategic Platform Guiding Outcomes Focused Customer Global Leadership Principles Solution Provider Relationships Success Factors Accelerate Operational Growth Excellence Our People & Values Talent Management CAPITAL MARKET DAY 2013
Slide 14: Accellerate Growth: Innovation System
Accellerate Growth STRENGTHEN INNOVATION SYSTEM: INNOVATION & PRODUCT DEVELOPMENT, MSEK More customer centric innovation process Create new markets / unmet needs Emphasize development of products with unique and proprietary recurring revenue streams Proven outcomes Strong product pipe-line
Slide 15: Accellerate Growth: Emerging Markets
Accellerate Growth INCREASED EXPOSURE TO EMERGING MARKETS: Strengthen existing tier 1 position and develop affordable tier 2 offering Continued investment in own sales infrastructure in developing economies Building critical mass through acquisitions in relevant developing economies - Acare, C
Slide 16: Accellerate Growth: External Growth
Accellerate Growth EXTERNAL GROWTH Bolt-on acquisitions will add approximately 2% growth per annum. Focus on new technologies and geographical expansion within existing product categories. Acquisitions of new and leading product lines that reinforces our capacities as a solution provider is expe
Slide 17: Bolt-on Acquisitions in Existing Product Categories
BOLT-ON ACQUISITIONS IN EXISTING PRODUCT ACQUISITIONS OF NEW CATEGORIES LEADING PRODUCT LINES Sterilization no 1 Integrated Infection Control solutions Disinfection no 1 Patient Handling no 1 Hygiene Systems no 1 Integrated solutions for Wound Care/TS no 2 health care ergonomics IPC/DVT no 2 Surgica
Slide 18: Operationel Excellence
Operationel Excellence EFFICIENCY Ongoing plant consolidation – from 26 to 18 Outsourcing of non core manufacturing activities Manufacturing and sourcing in low cost countries. We expect 30-40 % of our sourcing needs to originate from low-cost countries by 2013 (2012: 23%) Improved logistics
Slide 19: Outlook 2013
1 OVERVIEW & FUTURE DIRECTION 2 FINANCIAL TARGETS & HOW WE REACH THEM 3 OUTLOOK 2013 CAPITAL MARKET DAY 2013
Slide 20: Outlook 2013
Outlook 2013 Good earnings momentum excluding restructuring charges and despite 300 MSEK headwind from Medical Device Tax and less favourable hedging contracts Earnings growth will be stronger in H2 than in H1 and earnings in Q1 2013 will be lower than Q1 2012. The development of healthcare ca
Slide 21: Outlook 2013
Outlook 2013 % OF GROUP CHANGE REGION PRODUCT CATEGORY 2013 ORDERS % CAPITAL 17% -10% WE RECURRING 20% 3% ~3% CAPITAL 11% -6% NA RECURRING 21% 5% ~5% CAPITAL 23% 15% >10% ROW RECURRING 8% 9% ~10% CAPITAL 51% 1% 0–5% TOTAL RECURRING 49% 5% ~5% CAPITAL MARKET DAY 2013